The Best ASX Blue chip Stocks
to buy Now In October 2024

Check out our industry experts’ report and
Analysis on the best blue chip stocks right now on the ASX

The Best ASX Blue chip Stocks to buy Now In October 2024

Check out our industry experts’ report and analysis on the best blue chip stocks right now on the ASX

What are Blue Chip stocks?

Blue chip shares are the stocks of well-established companies with strong credit ratings and a long history of performance and stability. These companies tend to have dependable business models and strong credit ratings. Blue chip companies tend to be the market cap leaders, and blue chips themselves are typically the largest companies in their respective stock, market caps and sectors.

The term "blue to buy the most blue chip shares or own blue chips or buy blue-chip shares" is derived from poker, where the blue chips are the highest valued ones. In the Australian Securities Exchange (ASX), an exchange-traded fund many blue-chip shares, companies, stocks and companies are household names. Examples include NAB (National Australia Bank), CBA (Commonwealth Bank of Australia), BHP and CSL. Investing in blue-chip stocks or shares of these and other large-cap companies is a common strategy for achieving high capital growth.

Why invest in Blue Chip Stocks in Australia?

Investing in blue chip shares on the ASX offers several distinct advantages. For one, Australian blue chip shares come with the promise of financial stability. The blue chip companies listed on the ASX have demonstrated resilience in the face of market downturns, owing to their dependable business models and robust financials.

For instance, during periods of market volatility, resource companies, like BHP Group and National Australia Bank have consistently demonstrated their ability to weather economic downturns. Their company's annual reports reveal a strong track record of stability and growth.

Another major advantage is the potential for regular income from paying dividends. Blue chip stocks tend to pay higher dividends than smaller companies or penny stocks. For example, larger companies, such as the so-called Big Four Banks and major miners.

Get the Latest Stock Market Insights for Free with
Stocks Down Under & Pitt Street Research

Join our newsletter and receive exclusive insights, market trends, investment tips, and updates delivered directly to your inbox. Don't miss out!

A Unique Way to Invest in Blue Chip Shares: Exchange Traded Funds (ETFs)

For those looking to invest in blue-chip shares but finding it difficult to select individual stocks or purchase several at once, an alternative is to invest in Exchange Traded Funds (ETFs). ETFs provide a simple and cost-effective way to gain exposure to multiple blue-chip stocks through a single transaction.

ETFs that focus on blue-chip shares offer broad exposure to Australia's largest and most stable companies, which can include a mix of banks, resource companies, and retailers. Examples include the Vanguard Australian Shares Index ETF (VAS) or iShares S&P/ASX 200 ETF (IOZ), which track the performance of the ASX 200, giving investors access to top blue-chip companies like BHP, CBA, and Telstra. These ETFs also provide diversification, spreading investment risk across multiple sectors and companies, reducing the impact of poor performance from any single stock.

In addition to diversification, ETFs often come with lower fees compared to blue chip fund, making them an attractive option for investors looking for a more hands-off approach while still benefiting from the stability and growth potential of blue-chip stocks.

3 Best ASX Blue Chip Shares to Invest in for 2024

BHP Group (ASX: BHP)

As one of the world's largest mining companies by market capitalisation, BHP Group (ASX: BHP) is a major player in the mining industry. The company operates across several continents, with significant operations in Australia, South America, and Papua New Guinea. BHP Group has a diverse portfolio, including iron ore, metallurgical coal, copper, and oil.

Commonwealth Bank of Australia (ASX: CBA)

The Commonwealth Bank of Australia (ASX: CBA) is a classic example of a quality blue chip investment – ideal for those looking for consistent returns and financial stability. The bank made a $9.8bn profit and made a total of $8bn worth of shareholder returns through buybacks & divieends ($4.56 per share). It has an outstanding CET1 ratio of 12.3%, indicating strong financial resilience on the part of the institution.

CSL (ASX: CSL)

CSL is the ASX's largest healthcare stock, providing medical therapies such as flu vaccines and blood plasma products. Although investors have had some concerns - including slowing margins lately, the threat of Ozempic and concerns it paid too much for Vifor - CSL's management has told investors to expect double digit earnings growth for the rest of the decade.

3 Best ASX Blue Chip Shares to Invest in in 2024

BHP (ASX: BHP)

As one of the world's largest mining companies by market capitalisation, BHP (ASX: BHP) is a major player in the mining industry. The company operates across several continents, with significant operations in Australia, South America, and Papua New Guinea. BHP Group has a diverse portfolio, including iron ore, metallurgical coal, copper, and oil.

This diverse portfolio reduces the risk of individual commodities impacting the share price but also minimises any upside from short-term increases in these commodities. But crucially, the demand dynamics for iron ore and copper are strong in the long term. This makes it a standout amongst ASX mining stocks.

In FY24, the company generated US$55.7bn in revenue (up 3%), an attributable profit of US$7.9bn (down 39%) and an underlying attributable profit of US$13.7bn (up 2%). The difference between the two profits can be explained by the US$2.7bn impairment of its WA nickel assets and a US$3.8bn charge related to the Samarco dam failure, although these figures were partially offset by a US$0.7bn gain on the disposal of its Queensland coal assets.

If you're looking for dividends, BHP is worth considering. Although commodities stocks are volatile, BHP has a diversified portfolio of assets. With this and the company's promise to pay out at least 50% of its earnings in dividends, the company is one of the top dividend stocks. The company paid US$1.46 (A$2.15) per share in FY24, making its total cash returns to shareholders US$7.4bn (A$10.9bn).

In terms of diversification into exploration and production, operationally efficient BHP is in a better position to withstand any market volatility. These commodities are in high demand at almost all times. Therefore, the target zones of the company – copper, iron ore, and coal serve as a solid ground for the stability in revenues. What is more, BHP’s recent record of iron ore, whereby prices outperform expectations, suggests strong prospects of this company making profits.

The demands of key international markets, especially big economies such as China, greatly affect BHP’s performance. Also, given that some analysts are expecting higher iron ore prices as well as potential fiscal stimulus adding to increased steel demands, BHP should gain from such macroeconomic conditions.

Commonwealth Bank of Australia (ASX: CBA)

The Commonwealth Bank of Australia (ASX: CBA) is a classic example of a quality blue chip investment – ideal for those looking for consistent returns and financial stability.

CBA remains operationally stable to date even under margin pressures in the banking sector. Despite the adverse economic climate, it has maintained a consistent cash NPAT of ~$10bn over the last 3 years, which demonstrates its operational effectiveness. It paid $8bn in total returns through buybacks and dividends. It paid $4.86 per share in dividends in FY24, representing 79% of its profit.

The bank has an outstanding CET1 ratio of 12.3%, indicating strong financial resilience on the part of the institution.

Another thing that makes CBA special is that it puts a lot of attention to the maintenance of strong credit quality. Despite this, the bank portrays itself as a good risk manager because it has managed arrears that are relatively small compared to other banks; and this is a vital trait in a volatile economic environment. It also has a lower portion of its home loans sourced from brokers, thus avoiding paying trailing commissions to the extent its peers have to.

CSL Limited (ASX:CSL)

CSL is the ASX's largest healthcare stock. The company has a proud history, enabling many of the 20th century medical advances to reach our shores such as insulin, penicillin and flu vaccines. It was privatised and publicly listed in 1994 at $2.30 a share, although it undertook a three for one share split in 2007 making its IPO price 76.7c in real terms, meaning it has been more than a 300-bagger since listing!

CSL, has two primary businesses: flu vaccines and blood products – it takes plasma from donors and turns it into life-saving therapeutics, particularly immunoglobin products. Plasma is the substance that carries red and white blood cells through the body – these therapies are relevant for disorders such as hemophilia, primary immune deficiencies, hereditary angioedema and inherited respiratory disease.

CSL investors have had 3 major concerns about the stock. First that US$11.7bn was too much to pay for Vifor, which CSL acquired in late 2021. Second, the increased uptake of Ozempic may threaten its future markets - because if you reduce obesity, you reduce healthcare problems that CSL's products aim to treat. Third, margins being under pressure. Nonetheless, the company is expecting double-digit earnings growth for the rest of the decade and has told investors to be patient with Vifor. As for Ozempic, even if it does reduce obesity and health problems that come with it - it may not help people that already have the disease.

CSL just released its FY24 results. It delivered US$14.8bn in revenue and a $2.9bn post-tax profit, both up 11% from FY23. It paid a total dividend of US$2.64 per share, or A$4. The biggest contributor was the Behring segment which delivered US$10.6bn in sales, $5.7bn of which came from its Immunogobulin products including Privigen and Hizentra.

Analysts covering CSL have a mean price of A$317.62, a figure 7% higher than the current share price. They call for $15.8bn in revenue and $6.75 EPS for FY25 (or a $3.27bn profit) which would be in line with the company’s expectations. For FY26, $17bn in revenue (up 7.6%) and $7.81 EPS or a $3.8bn profit (up 16%). The company is trading at 7x EV/Sales, 20.3x EV/EBITDA, 29.2x P/E and 2.1x PEG – all hefty multiples for an ASX company.

We think investors who hold for 10-20 years won’t be disappointed in buying CSL now. However, it won’t generate ‘quick’ returns, so those investors shouldn’t buy CSL. One forthcoming catalyst may be sales from HEMGENIX, the first ever FDA-approved gene therapy for hemophilia B, that is one of the world’s most expensive drugs, costing US$3.5m. Although a new drug won’t be as much of a catalyst for a share price spike than it would be with a clinical stage biotech with just one or two assets.

Pros and Cons of Investing in Blue Chip Companies Australia

Adding blue-chip stocks to the investment portfolio may improve the overall returns since they are more likely to outperform their peers in the market cap in terms of return prospects. The historical performance of such companies has always been on the upward trend. The ASX All ordinaries index has a long two-decade average of about 10%, while bonds have been averaging at 5% annually over the same period.

In essence, blue chip companies refer to big old companies that continuously make profits and provide market stability amidst volatility and uncertainty. Moreover, there are many dividend-paying stocks among these which make stable streams of income that work especially well for the pensioners. Additionally, their long-term growth rate has been impressive with the ASX All Ordinaries index averaging of 12% p.a over the last 50 years, taking a ten-year-old investment to around $ 1 million.

Nonetheless, this has some drawbacks. Blue chip stocks are slightly less risky but may still encounter market fluctuations and downturns during an economic recession. They go down during poor business times although they normally recover as time goes by. However, while it is important to consider these stocks for your portfolio, not everyone comes with an equal measure of safety or profitability.

The fact that individual stock performance varies underscores the significance of holding various high-yield shares. In addition, such stocks are not for everyone, particularly conservative investors who have other securities in their portfolios, including bonds, or even cash.

How to Choose the Right ASX Blue Chip Stocks

Investors often wonder about the right investment time frame to invest in multiple blue chip stocks and shares. While some may argue that any time is a good time due to the long-term stability and growth potential that these stocks tend to offer younger investors, it's wise to consider market conditions and company fundamentals before making an investment decision.

Understanding market cycles is crucial for timing your investment in blue chip shares. During periods of economic growth, we buy blue chip stocks and shares that can provide stable returns and dividends. During downturns, while they may take a hit, they often recover quicker than smaller, less-established companies due to their financial resilience.

Another key factor is the company's financial health, which can be assessed by examining the company's annual reports and financial statements. Companies with low debt, strong cash flows, and steady revenue growth are typically better positioned to weather financial turbulence.

Lastly, consider the company's price-to-earnings (P/E) ratio. A high P/E ratio might indicate that the company's shares are overpriced, and waiting for a correction could be beneficial. Conversely, a low P/E ratio might indicate undervalued growth companies, presenting a potentially favorable investment opportunity.

The Risks: Understanding the Potential Downfalls of Blue Chip Investments

While Australian blue chip stocks tend to offer stability, consistent dividends, and potential for high capital growth, it's essential to understand the potential risks associated with these investments. One potential risk is over-reliance on a single sector. For example, if your portfolio is heavily weighted toward the financial sector, it may suffer significant losses in a banking crisis. Therefore, it's essential to maintain a diversified portfolio across different market sectors throughout.

Another risk is the potential for slower growth. Although blue chip companies tend to be more stable and less volatile than smaller companies or start-ups, they may not provide the same rapid growth opportunities. Their size can make it challenging to sustain high growth rates, and they may not be as agile or innovative as smaller, emerging companies.

Finally, while blue chip stocks are often perceived as 'safe' investments, they are still subject to market risks. Economic downturns, regulatory changes, or company-specific issues can lead to losses. Therefore, it's crucial to conduct thorough research and consider seeking advice from financial professionals before investing.

FAQs on Investing in Blue Chip Stocks Australia

What are blue chip shares?

Blue chip shares are stocks of large, well-established companies with strong financial histories, stability, and a reputation for consistent performance and paying dividends.

How can I buy blue-chip stocks on the ASX?

Are blue chip stocks only suitable for long-term investing?

Do blue chip stocks pay dividends?

Are blue-chip stocks a good investment?

What are the best blue chip shares to buy on the ASX?

Is Rio Tinto a blue chip stock?

Is Commonwealth Bank a blue chip stock?